PedAM
Pediatric Disease Annotations & Medicines
| colitis | ||||
| Disease ID | 726 |
|---|---|
| Disease | colitis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:15) C0011991 | diarrhea | 34 C0009402 | colorectal cancer | 26 C0007102 | colon cancer | 14 C1510475 | diverticulosis | 13 C0008311 | cholangitis | 11 C0025160 | megacolon | 8 C0011991 | diarrhoea | 8 C0085652 | pyoderma gangrenosum | 7 C0021311 | infections | 5 C0003864 | arthritis | 3 C0009402 | colorectal carcinoma | 2 C0240805 | prodrome | 2 C0026946 | fungal infection | 1 C0032568 | pseudopolyposis | 1 C0020541 | portal hypertension | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:8) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs121918338 | 25702837 | 64170 | CARD9 | umls:C0009319 | BeFree | All patients were found to be homozygous for rare and deleterious mutant CARD9 alleles: R70W and Q289* for the 3 patients with Candida albicans-induced meningoencephalitis, R35Q for the patient with meningoencephalitis and colitis caused by Candida glabrata, and Q295* for the patient with Candida albicans-induced colitis. | 0.000271442 | 2014 | CARD9 | 9 | 136370362 | G | A |
| rs149491038 | 21519361 | 6774 | STAT3 | umls:C0009319 | BeFree | In contrast to our original hypothesis, no defect of the anti-inflammatory potential of TGFβ and IL10 was observed in children with IBD or EO-IBD except two infants who presented with granuloma-positive colitis at 3 months of life: no response to IL10 was observed secondary to mutations in the α (p.R262C) or β (p.E141X) chain of IL10R, respectively, although a fully functional Jak-STAT3 pathway was present in both patients. | 0.003800186 | 2011 | IL10RA | 11 | 117995684 | C | T |
| rs149491038 | 21519361 | 3587 | IL10RA | umls:C0009319 | BeFree | In contrast to our original hypothesis, no defect of the anti-inflammatory potential of TGFβ and IL10 was observed in children with IBD or EO-IBD except two infants who presented with granuloma-positive colitis at 3 months of life: no response to IL10 was observed secondary to mutations in the α (p.R262C) or β (p.E141X) chain of IL10R, respectively, although a fully functional Jak-STAT3 pathway was present in both patients. | 0.000542884 | 2011 | IL10RA | 11 | 117995684 | C | T |
| rs149491038 | 21519361 | 3586 | IL10 | umls:C0009319 | BeFree | In contrast to our original hypothesis, no defect of the anti-inflammatory potential of TGFβ and IL10 was observed in children with IBD or EO-IBD except two infants who presented with granuloma-positive colitis at 3 months of life: no response to IL10 was observed secondary to mutations in the α (p.R262C) or β (p.E141X) chain of IL10R, respectively, although a fully functional Jak-STAT3 pathway was present in both patients. | 0.221725281 | 2011 | IL10RA | 11 | 117995684 | C | T |
| rs149491038 | 21519361 | 27034 | ACAD8 | umls:C0009319 | BeFree | In contrast to our original hypothesis, no defect of the anti-inflammatory potential of TGFβ and IL10 was observed in children with IBD or EO-IBD except two infants who presented with granuloma-positive colitis at 3 months of life: no response to IL10 was observed secondary to mutations in the α (p.R262C) or β (p.E141X) chain of IL10R, respectively, although a fully functional Jak-STAT3 pathway was present in both patients. | 0.002442977 | 2011 | IL10RA | 11 | 117995684 | C | T |
| rs16967637 | 23929016 | 6777 | STAT5B | umls:C0009319 | BeFree | Single nucleotide polymorphism rs16967637 in the STAT5 gene was associated with small-bowel sparing Crohn's disease when the enteritis group was compared with either a combined colitis/ileocolic group (p = 0.025) or those with only ileocolic disease (p = 0.04). | 0.000542884 | 2013 | STAT5A | 17 | 42294404 | C | A |
| rs3939286 | 23634226 | 90865 | IL33 | umls:C0009319 | BeFree | Upon genotype-phenotype evaluation, an increased frequency of extensive colitis in adult UC (P = 0.019) and in steroid-responsive pediatric patients (P = 0.024) carrying the IL-33 rs3939286 risk genotype, was observed. | 0.001085767 | 2013 | NA | 9 | 6210099 | T | C |
| rs398122363 | 25702837 | 64170 | CARD9 | umls:C0009319 | BeFree | All patients were found to be homozygous for rare and deleterious mutant CARD9 alleles: R70W and Q289* for the 3 patients with Candida albicans-induced meningoencephalitis, R35Q for the patient with meningoencephalitis and colitis caused by Candida glabrata, and Q295* for the patient with Candida albicans-induced colitis. | 0.000271442 | 2014 | CARD9 | 9 | 136370380 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:15) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0009319 | amiloride | D000584 | 2609-46-3 | colitis | MESH:D003092 | therapeutic | 12065299 | ||
| C0009319 | ampicillin | D000667 | 69-53-4 | colitis | MESH:D003092 | marker/mechanism | 2306432 | ||
| C0009319 | arsenic trioxide | C006632 | 1327-53-3 | colitis | MESH:D003092 | therapeutic | 20693187 | ||
| C0009319 | dapsone | D003622 | 80-08-0 | colitis | MESH:D003092 | marker/mechanism | 19583683 | ||
| C0009319 | foscarnet | D017245 | 4428-95-9 | colitis | MESH:D003092 | therapeutic | 11362300 | ||
| C0009319 | glutathione | D005978 | 70-18-8 | colitis | MESH:D003092 | marker/mechanism | 23810507 | ||
| C0009319 | indomethacin | D007213 | 53-86-1 | colitis | MESH:D003092 | therapeutic | 11137876 | ||
| C0009319 | methotrexate | D008727 | 1959/5/2 | colitis | MESH:D003092 | marker/mechanism | 5410994 | ||
| C0009319 | nicotine | D009538 | - | colitis | MESH:D003092 | therapeutic | 23810507 | ||
| C0009319 | nitric oxide | D009569 | 10102-43-9 | colitis | MESH:D003092 | marker/mechanism | 17449036 | ||
| C0009319 | rosiglitazone | C089730 | - | colitis | MESH:D003092 | therapeutic | 21893696 | ||
| C0009319 | thalidomide | D013792 | 50-35-1 | colitis | MESH:D003092 | therapeutic | 16680017 | ||
| C0009319 | tretinoin | D014212 | 302-79-4 | colitis | MESH:D003092 | marker/mechanism | 10741706 | ||
| C0009319 | tretinoin | D014212 | 302-79-4 | colitis | MESH:D003092 | therapeutic | 17035595 | ||
| C0009319 | troglitazone | C057693 | 97322-87-7 | colitis | MESH:D003092 | therapeutic | 11346461 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003092 | inomax | nitric oxide | 100PPM Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | GAS;INHALATION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003092 | 12/21/2010 | inomax | nitric oxide | Prevention of bronchopulmonary dysplasia | INOmax is not indicated for prevention of BPD in preterm neonates d 34 weeks gestational age.Efficacy for the prevention of BPD in preterm infants was not established in three ldouble-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants Information on clinical trials, adverse reaction | Labeling | B | - | - | - | INO Therapeutics | 2/11/2010 | FALSE' |